natgillin/translations-raw huggingface dataset:
Patients on aspirin and a more potent P2Y12 blocker and without adverse event at one month were assigned to switch to fixed-dose aspirin plus clopidogrel (de-escalated dual antiplatelet therapy (DAPT)) or continuation of their drug regimen (unchanged DAPT). 
Bolesnici na aspirinu i jačem blokatoru P2Y12 bez nuspojava nakon mjesec dana raspoređeni su za prebacivanje na fiksnu dozu aspirina plus klopidogrel (deeskalirana dualna antitrombocitna terapija (DAPT)) ili za nastavak svog režima lijeka (neizmijenjeni DAPT).
In all aluminium blisters, this medicinal product does not require any special storage conditions. 
Aluminijski blisteri: lijek ne zahtijeva posebne uvjete čuvanja.
In TRITON-TIMI 38 and 3 of the cohort studies (Collet, Sibbing, Giusti) the combined group of patients with either intermediate or poor metaboliser status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers. 
U studiji TRITON-TIMI 38 i 3 kohortne studije (Collet, Sibbing, Giusti), kombinirana skupina bolesnika sa statusom slabih ili umjerenih metabolizatora, imala je veću stopu kardiovaskularnih događaja (smrt, infarkt miokarda, i moždani udar) ili tromboze stenta, u usporedbi s brzim metabolizatorima.
The guided de-escalation did not result in an increased combined risk of ischemic events (2.5% in the deescalation group vs 3.2% in the control group; p non-inferiority=0.0115), nor in the key secondary endpoint of BARC bleeding ≥2 ((5%) in the de-escalation group versus 6% in the control group (p=0.23)). 
Kontrolirana deeskalacija nije dovela do povećanog kombiniranog rizika od ishemijskih događaja (2,5 % u skupini s deeskalacijom u odnosu na 3,2 % u kontrolnoj skupini; p neinferiornost=0,0115), niti do ključnog sekundarnog ishoda krvarenja kategorije ≥2 prema BARC-u ((5 %) u skupini s deeskalacijom u odnosu na 6 % u kontrolnoj skupini (p=0,23).
In a randomised, double-blind, parallel-group study (CLARINET), 906 paediatric patients (neonates and infants) with cyanotic congenital heart disease palliated with a systemic-to-pulmonary arterial shunt were randomised to receive clopidogrel 0.2 mg/kg (n=467) or placebo (n=439) along with concomitant background therapy up to the time of second stage surgery. 
U randomiziranoj, dvostrukoslijepoj studiji s paralelnim skupinama (CLARINET), 906 pedijatrijskih bolesnika (novorođenčad i dojenčad) s cijanotičnom kongenitalnom bolešću srca ublaženom sistemskoplućnim arterijskim šantom, bilo je randomizirano da primaju klopidogrel u dozi od 0,2 mg/kg (n=467) ili placebo (n=439) zajedno s istodobnom popratnom terapijom sve do drugog operativnog zahvata.
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics). 
Prevalencija CYP2C19 alela koji rezultiraju umjerenim i slabim CYP2C19 metabolizmom razlikuje seprema rasi/etničkoj skupini (vidjeti dio "Farmakogenetika").
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible side effects'). 
Ukoliko ste ipak zabrinuti zbog krvarenja, odmah obavijestite svog liječnika (pogledajte dio 4. "Moguće nuspojave").
Clopidogrel Apotex is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Apotex uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Warnings and precautions'). 
Ukoliko ste ipak zabrinuti zbog krvarenja, odmah obavijestite svog liječnika.(vidjeti dio 2. "Upozorenja i mjere opreza").
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen,and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen. 
Dodatno, vrijednost IPA iznosila je 32% (24 sata) i 61% (dan 5), što je više nego u slabih metabolizatora koji su primali režim doziranja od 300 mg/75 mg i slično je ostalim skupinama CYP2C19 metabolizatora koje su primale doze od 300 mg/75 mg.
Driving and using machines Clopidogrel Apotex is unlikely to affect your ability to drive or to use machines. 
Upravljanje vozilima i strojevima: Clopidogrel Apotex ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
Clopidogrel Apotex film-coated tablets are pink, round and biconvex. 
Clopidogrel Apotex filmom obložene tablete su ružičaste, okrugle i bikonveksne.
For further information please refer to section 5.1. 
Za dodatne informacije molimo vidjeti dio 5.1. 4.2 Doziranje i način primjene Doziranje
In patients suffering from acute coronary syndrome: 
• odraslih bolesnika koji boluju od akutnog koronarnog sindroma:
Follow-up at one year was performed for 316 patients (98.1%) in the de-escalated DAPT group and 318 patients (98.5%) in the unchanged DAPT group. 
Praćenje nakon godinu dana obavljeno je za 316 bolesnika (98,1 %) u skupini s deeskaliranim DAPT-om i 318 bolesnika (98,5 %) u skupini s neizmijenjenim DAPT-om.
Medicinal products that are strong or moderate CYP2C19 inhibitors include for example omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, and efavirenz. 
Lijekovi koji su jaki ili umjereni inhibitori CYP2C19 uključuju, primjerice, omeprazol i esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, karbamazepin i efavirenz.
If you take more Clopidogrel Apotex than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Odmah morate kontaktirati liječnika ili najbliži odjel hitne medicinske pomoći zbog povećanog rizika od krvarenja.
The primary endpoint (the combined incidence of CV death, MI, stroke and BARC bleeding grade ≥2 at 12 months) was met showing non-inferiority. 
Primarni ishod (kombinirana učestalost kardiovaskularne smrti, infarkta miokarda, moždanog udara i krvarenja kategorije ≥2 prema BARC-u nakon 12 mjeseci) ispunjen je uz dokaz o neinferiornosti.
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non-fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins. 
Fibrinolitike je primalo 99,7% bolesnika (fibrin-specifični: 68,7%, fibrinnespecifični: 31,1%), 89,5% heparin, 78,7% beta blokatore, 54,7% ACE inhibitore i 63% statine.
- In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. 
U odraslih bolesnika s fibrilacijom atrija koji imaju najmanje jedan faktor rizika za krvožilne događaje, nisu podobni za terapiju antagonistima vitamina K (VKA) te imaju nizak rizik od krvarenja, klopidogrel je indiciran u kombinaciji s ASK za prevenciju aterotrombotičkih i tromboembolijskih događaja, uključujući moždani udar.
What Clopidogrel Apotex looks like and contents of the pack 
Kako Clopidogrel Apotex izgleda i sadržaj pakiranja
TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes) 
TROPICAL-ACS (Testiranje responsivnosti inhibicije trombocita na kronično antitrombocitno liječenje za akutne koronarne sindrome [Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet
Ninety five patients (7%) in the guided de-escalation group and 118 patients (9%) in the control group (p non-inferiority=0.0004) had an event. 
Kod 95 bolesnika (7 %) u skupini s kontroliranom deeskalacijom i kod 118 bolesnika (9 %) u kontrolnoj skupini (p neinferiornost=0,0004) zabilježen je događaj.
This statistically significant difference was mainly driven by fewer bleeding events, with no difference reported in ischaemic endpoints (p=0.36), while BARC ≥2 bleeding occurred less frequently in the de-escalated DAPT group (4.0%) versus 14.9% in the unchanged DAPT group (p<0.01). 
Ova statistički značajna razlika bila je uglavnom posljedica manjim brojem krvarenja, bez zabilježene razlike u ishemijskim ishodima (p=0,36), dok se krvarenje kategorije ≥2 javljalo rjeđe u skupini s deeskaliranim DAPT-om (4,0 %) u odnosu na 14,9 % u skupini s neizmijenjenim DAPT-om (p<0,01).
Pink, round, biconvex, film-coated tablets. 
Ružičasta, okrugla, bikonveksna filomom obložena tableta.
TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome) 
TOPIC (Vrijeme inhibicije trombocita nakon akutnog koronarnog sindroma [Timing Of Platelet
This randomized, open-label trial included ACS patients requiring PCI. 
Ovo randomizirano, otvoreno ispitivanje uključivalo je bolesnike s ACS-om kojima je bila neophodna perkutana koronarna intervencija (PCI).
What you need to know before you take Clopidogrel Apotex 
Što morate znati prije nego počnete uzimati Clopidogrel Apotex
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. 
Akutni infarkt miokarda s elevacijom ST-segmenta, u kombinaciji s ASK u medikamentozno liječenih bolesnika pogodnih za liječenje trombolitičkom terapijom.
Therefore, concomitant use of clopidogrel with boosted ART should be discouraged. 
Stoga istodobnu primjenu klopidogrela s pojačanim terapijama ARTa treba izbjegavati.
They are supplied in PVC/PE/PVDC/Alu blisters or in PA/ALL/PVC-Alu blisters packed in cartons containing 7, 14, 28, 30, 50, 56, 84, 90 or 100 film-coated tablets. 
Dostupne su u PVC/PE/PVDC/Al blisterima ili PA/ALL/PVC-Al blisterima u pakiranjima koja sadrže: 7, 14, 28, 30, 50, 56, 84, 90 ili 100 filmom obloženih tableta.
Overall, 645 of 646 patients with STEMI or NSTEMI or unstable angina were analyzed (de-escalated DAPT (n=322); unchanged DAPT (n=323)). 
Ukupno je analizirano 645 od 646 bolesnika s infarktom miokarda sa ST elevacijom (STEMI) ili infarktom miokarda bez ST elevacije (NSTEMI) ili nestabilnom anginom pektoris (deeskalirani DAPT (n=322); neizmijenjeni DAPT (n=323).
rash erythematous or exfoliative, urticaria, eczema, lichen planus 
DRESS), eritematozni ili eksfolijativni osip, urtikarija, ekcem, lichen planus
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers. 
U skladu s gore navedenim rezultatima, u metaanalizi koja je uključivala 6 studija sa 335 osoba liječenih klopidogrelom u stanju dinamičke ravnoteže, pokazano je da je izloženost aktivnom metabolitu smanjena za 28% za umjerene metabolizatore te 72% za slabe metabolizatore, dok je inhibicija agregacije trombocita (5 μM ADP) smanjena s razlikama za vrijednsoti IPA-e od 5,9%, odnosno 21,4%, u usporedbi s brzim metabolizatorima.
The primary outcome, a composite of cardiovascular death, stroke, urgent revascularization, and BARC (Bleeding Academic Research Consortium) bleeding ≥2 at 1 year post ACS, occurred in 43 patients (13.4%) in the de-escalated DAPT group and in 85 patients (26.3%) in the unchanged DAPT group (p<0.01). 
Primarni ishod, kompozit kardiovaskularne smrti, moždanog udara, urgentne revaskularizacije i krvarenja kategorije ≥2 prema BARC-u (Akademski istraživački konzorcij za krvarenje) nakon 1 godine poslije ASC-a, zabilježen je kod 43 bolesnika (13,4 %) u skupini s deeskaliranim DAPT-om i kod 85 bolesnika (26,3 %) u skupini s neizmijenjenim DAPT-om (p<0,01).
cross reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)* 
Poremećaji imunološkog sustava serumska bolest, anafilaktoidne reakcije, križno reaktivna preosjetljivost na lijekove iz skupine tienopiridina (kao što su tiklopidin, prasugrel) (vidjeti dio 4.4)*, inzulinski autoimuni sindrom, koji može dovesti do teške hipoglikemije, osobito u bolesnika s podtipom HLA DRA4 (češće se javlja u japanskoj populaciji)*
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidegrel Apotex per day to be taken orally with or without food, and at the same time each day. 
Preporučena doza Clopidogrel Apotexa, uključujući dozu za bolesnike sa stanjem koje se naziva „fibrilacija atrija“ (nepravilni otkucaji srca), je jedna tableta od 75 mg dnevno koja se uzima kroz usta, s obrokom ili između obroka, u isto vrijeme svaki dan.
The clinical benefit provided by the more potent P2Y12 inhibitors, ticagrelor and prasugrel, in their pivotal studies is related to a significant reduction in recurrent ischaemic events (including acute and subacute stent thrombosis (ST), myocardial infarction (MI), and urgent revascularization). 
Klinička korist koju su pružali jači inhibitori P2Y12, tikagrelor i prasugrel, u svojim pivotalnim ispitivanjima, odnosila se na značajno smanjenje reukrentnih ishemijskih događaja (uključujući akutnu i subakutnu trombozu stenta, infarkt miokarda i urgentnu revaskularizaciju).
Bleeding events defined as all BARC occurred in 30 patients (9.3%) in the de-escalated DAPT group and in 76 patients (23.5%) in the unchanged DAPT group (p<0.01). 
Slučajevi krvarenja definirani kao sva krvarenja prema BARC-u zabilježena su kod 30 bolesnika (9,3 %) u skupini s deeskaliranim DAPT-om i kod 76 bolesnika (23,5 %) u skupini s neizmijenjenim DAPT-om (p<0,01).
If Clopidogrel Apotex is supplied in PVC/PE/PVDC/aluminium blisters, store below 25°C. 
Ako je Clopidogrel Apotex opremljen u PVC/PE/PVDC/aluminijske blistere, čuvati na temperaturi ispod 25°C.
Each film-coated tablet contains 2.5 mg of lactose (as monohydrate). 
Jedna filmom obložena tableta sadrži 2,5 mg laktoze (u obliku hidrata).
• If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain. 
• ako imate poremećaj koji izaziva krvarenje, kao što je, primjerice, želučani čir ili krvarenje u mozgu;
What Clopidogrel Apotex contains The active substance is clopidogrel. 
Što Clopidogrel Apotex sadrži Djelatna tvar je klopidogrel.
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5). 
Kao i u slučaju drugih antitrombocitnih lijekova, klopidogrel s oprezom treba davati bolesnicima koji su izloženi povećanom riziku od krvarenja zbog povrede, kirurških zahvata ili drugih patoloških stanja te bolesnicima koji se liječe s ASK, heparinom, inhibitorima glikoproteina IIb/IIIa ili nesteroidnim protuupalnim lijekovima (NSAIL), uključujući Cox-2 inhibitore ili selektivne inhibitore ponovne pohrane serotonina (SSRI) ) ili druge lijekove povezane s rizikom od krvarenja kao što je pentoksifilin (vidjeti dio 4.5).
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking Clopidogrel 75 mg/day. 
S dozom od 0,2 mg/kg postignut je prosječni postotak inhibicije od 49,3% (5 µM ADP-om inducirane agregacije trombocita), što je usporedivo s postotkom u odraslih koji uzimaju klopidogrel u dozi od 75 mg/dnevno.
You should specifically tell your doctor if you take medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints, o heparin or any other injectable medicine used to reduce blood clotting, o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, omeprazole or esomeprazole, medicines to treat upset stomach, fluconazole or voriconazole, medicines to treat fungal infections, 
Posebno je važno obavijestiti liječnika ako uzimate lijekove koji mogu povećati rizik od krvarenja, na primjer: o oralne antikoagulanse, lijekove koji smanjuju zgrušavanje krvi, o nesteroidne protuupalne lijekove, koji se obično primjenjuju za liječenje bolnih i/ili upalnih stanja mišića ili zglobova, o heparin ili bilo koji drugi lijek koji se daje putem injekcije za smanjivanje zgrušavanja krvi, o tiklopidin, drugi antitrombocitni lijek, o selektivne inhibitore ponovne pohrane serotonina (uključujući, ali ne ograničeno na fluoksetin ili fluvoksamin), lijekove koji se obično koriste za liječenje depresije,
Then, the recommended dose is one 75-mg tablet of Clopidogrel Apotex per day as described above. 
Apotexa je jedna tableta od 75 mg dnevno kako je prethodno opisano.
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
Bolesnici s akutnim koronarnim sindromom: Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
Switching from a more potent P2Y12 receptor inhibitor to clopidogrel in association with aspirin after acute phase in ACS has been evaluated in two randomized investigator-sponsored studies (ISS)TOPIC and TROPICAL-ACS - with clinical outcome data. 
Deeskalacija inhibitora P2Y12 kod akutnog koronarnog sindroma (ACS) Prebacivanje s jačeg inhibitora receptora P2Y12 na klopidogrel u kombinaciji s aspirinom nakon akutne faze ACS-a procijenjeno je u dva randomizirana ispitivanja koja su pokrenuli ispitivači (ISS)ispitivanja TOPIC i TROPICAL-ACS - s podacima o kliničkom ishodu.
In PVC/PE/PVDC/aluminium blisters, store below 25°C. 
PVC/PE/PVDC/aluminij blisteri: čuvati na temperaturi ispod 25°C.
Packs of 7, 14, 28, 30, 50, 56, 84, 90 or 100 film-coated tablets. 
Pakiranja sa 7, 14, 28, 30, 50, 56, 84, 90 ili 100 filmom obloženih tableta.
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). 
U post-hoc analizi 2.172 bolesnika (17% ukupne CURE populacije) koji su se podvrgli ugradnji stenta (Stent-CURE), podaci su pokazali da je klopidogrel u usporedbi s placebom, pokazao značajno smanjenje relativnog rizika od 26,2% za koprimarni ishod (kardiovaskularna smrt, infarkt miokarda, moždani udar) kao i značajno smanjenje relativnog rizika od 23,9% za drugi koprimarni ishod (kardiovaskularna smrt, infarkt miokarda, moždani udar ili refraktorna ishemija).
Rare side effect (may affect up to 1 in 1000 people): Vertigo, enlarged breasts in males. 
Rijetke nuspojave (mogu se javiti u manje od 1 na 1000 osoba): Vrtoglavica, povećanje grudi kod muškaraca.
The other ingredients are (see section 2 ‘Clopidogrel Apotex contains lactose'): Tablet core: hydroxypropylcellulose (E463), mannitol (E421), crospovidone (type A), citric acid monohydrate, microcrystalline cellulose, macrogol 6000, stearic acid, talc Tablet coating: lactose monohydrate (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172) and titanium dioxide (E171), 
Jezgra tablete: hidroksipropilceluloza (E463), manitol (E421), krospovidon (tip A), citratna kiselina hidrat, mikrokristalična celuloza, makrogol 6000, stearatna kiselina, talk Ovojnica tablete: laktoza hidrat (mliječni šećer), hipromeloza (E464), triacetin (E1518), crveni željezov oksid (E172) i titanijev dioksid (E171),
Hydroxypropylcellulose (E463) Mannitol (E421) Crospovidone (type A) Citric acid, monohydrate Macrogol 6000 
hidroksipropilceluloza (E463) manitol (E421) krospovidon (tip A) citratna kiselina, hidrat makrogol 6000 celuloza, mikrokristalična stearatna kiselina talk
Common side effects (may affect up to 1 in 10 people: Diarrhoea, abdominal pain, indigestion or heartburn. 
Česte nuspojave (mogu se javiti u manje od 1 na 10 osoba): proljev, bol u trbuhu, probavne tegobe ili žgaravica.
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia 
Trombotična trombocitopenična purpura (TTP, vidjeti dio 4.4.), aplastična anemija, pancitopenija, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija
Clopidogrel Apotex contains lactose. 
Apotex sadrži laktozu.
- ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with ASA and with or without thrombolytics. 
Akutni infarkt miokarda s elevacijom ST-segmenta: liječenje klopidogrelom provodi se jednom dnevnom dozom od 75 mg, a započinje udarnom dozom od 300 mg u kombinaciji s ASK te sa ili bez trombolitika.
• If you are allergic (hypersensitive) to clopidogrel or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Clopidogrel Apotex • ako ste alergični (preosjetljivi) na klopidogrel ili neki drugi sastojak ovog lijeka (naveden u dijelu
Patients were randomized to receive either prasugrel 5 or 10 mg/d (Days 0-14) (n=1309), or prasugrel 5 or 10 mg/d (Days 0-7) then de-escalated to clopidogrel 75 mg/d (Days 8-14) (n=1309), in combination with ASA (<100 mg/day). 
Bolesnici su randomizirani da primaju prasugrel od 5 ili 10 mg/dan (0.-14. dan) (n=1309) ili prasugrel od 5 ili 10 mg/dan (0.-7. dan) nakon čega je slijedila deeskalacija na klopidogrel od 75 mg/dan (8.-14. dan) (n=1309), u kombinaciji s ASA-om (<100 mg/dan).
Other medicines and Clopidogrel Apotex 
Drugi lijekovi i Clopidogrel
Very rare, 
Manje često
Clopidogrel Apotex contains lactose: 
Apotex sadrži laktozu:
PC: SN: NN: 
SN: {broj}
How to take Clopidogrel Apotex 
Kako uzimati Clopidogrel Apotex
Reproductive systems and breast disorders 
Poremećaji reproduktivnog sustava i dojki
Clopidogrel Apotex 75 mg film-coated tablets clopidogrel 
Clopidogrel Apotex 75 mg filmom obložene tablete klopidogrel
NAME OF THE MEDICINAL PRODUCT Clopidogrel Apotex 75 mg film-coated tablets 
NAZIV LIJEKA Clopidogrel Apotex 75 mg filmom obložene tablete
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Apotex: 
Ako se na Vas odnosi bilo koje od dolje navedenih stanja morate obavijestiti liječnika, prije nego što uzmete Clopidogrel Apotex:
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Apotex 
Ako se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja Clopidogrel Apotexa.
Clopidogrel Apotex with food and drink Clopidogrel Apotex may be taken with or without food. 
Apotex se može uzimati s obrokom ili bez obroka.
Gyanecomastia 
Ginekomastija